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Abstract
The combination of positron emission tomography (PET) with computed tomography (PET-CT) provides simultaneous
metabolic and anatomic information on tumors in the same imaging session. Sensitivity of PET/PET-CT is higher for
intrahepatic (90%) than for extrahepatic cholangiocarcinoma (CCA) (about 60%). The detection rate of distant
metastasis is 100%. PET, and particularly PET-CT, improves the results and impacts on the oncological management in
CCA compared with other imaging modalities. Therefore, PET-CT is recommended in the preoperative staging of
intrahepatic (strength of recommendation: moderate) and extrahepatic (strength of recommendation: low) CCA.
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Introduction
Cholangiocarcinoma (CCA) is a rare disease account-
ing for B2% of all human malignancies. In some
patients, surgery currently offers the only chance for
long-term survival and cure [1,2]. The differential
diagnosis includes both benign and malignant dis-
eases, such as pancreatic head carcinoma, ampulla
of Vater carcinoma, Mirizzi’s syndrome, benign stric-
tures, primary sclerosing cholangitis, and echinococ-
cosis. An extensive work-up is mandatory if tumor
stage is to be defined accurately, with a particular
emphasis on detecting distant metastases to identify
the patients who may benefit from surgery. Modalities
of imaging work-up include ultrasound, spiral con-
trast-enhanced computed tomography (ceCT), mag-
netic resonance imaging (MRI), magnetic resonance
cholangiopancreatography (MRCP), and more inva-
sive techniques, such as endoscopic retrograde cho-
langiopancreatography (ERCP) or percutaneous
transhepatic cholangiography (PTC).
The PET technique
In contrast to these imaging modalities, positron
emission tomography (PET) provides metabolic in-
formation on tumors, rather than anatomical data on
the localization of a lesion. This technique avails the
high utilization of glucose in tumor cells. As a
radiolabeled tracer, the 18F-fluoro-2-deoxy-D-glu-
cose (18 FDG) is transported into tumor cells by
membrane glucose transporter proteins (GLUT). 18
FDG is phosphorylated by hexokinase to FDG-
6-phosphate, a highly polar molecule which cannot
diffuse out of cell. The higher rates of phosphoryla-
tion due to an overexpressed hexokinase in malignant
cells lead to increased metabolism of the glucose in
cancer tissue which is visualized by PET.
However, PET is limited by poor resolution and
poor anatomic localization of positive lesions, and as a
result the diagnosis must ultimately rely on an
approximate correlation between findings obtained
on CT or MRI and the PET scan. To overcome this
limitation, a new technique combining data of a full
ring PET scanner with a multidetector row helical CT
in the same imaging session has been developed (PET-
CT) [3]. With this technology, the PET positive
lesions are projected directly into the CT scan to
obtain simultaneous metabolic and anatomic infor-
mation.
Trials
There are still few trials published on PET
in intrahepatic and/or extrahepatic CCA (Table I)
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[410]. Most studies are focused on staging by PET
alone; only two of them evaluate PET-CT. All of the
trials are cohort studies on consecutive patients with a
relatively low number of patients.
PET alone
The sensitivity of PET (without CT) is higher
compared to ceCT in intrahepatic CCA, ranging
between 91% and 95%. For extrahepatic CCA, the
sensitivity to detect the primary tumor is between
60% and 90%, which is comparable to ceCT. The
discrimination between primary tumor and local
lymph node metastases in PET scan is difficult,
therefore the sensitivity of local lymph node metas-
tasis PET is low (between 13% and 50%). In contrast,
the detection rate for distant metastases is high, PET
sensitivity having been reported between 65% and
94%. In the particular situation of primary sclerosing
cholangitis, PET has been reported as a useful tool for
excluding CCA (sensitivity of 75% and specificity of
95%).
PET-CT
PET-CT in cases of CCA have only been evaluated in
two studies. According to Petrowsky et al. [8], the
sensibility and specificity of PET-CT for intrahepatic
CCA (93% and 80%, respectively) are better than of
ceCT. For extrahepatic CCA, the values of PET-CT
are 55% (sensitivity) and 33% (specificity), which is
comparable to ceCT. In the same study, the sensitivity
and sensibility of PET-CT for detection of distant
metastases was 100% each; however, the sensitivity of
regional LN metastases was 12% (specificity of 96%).
Javar et al. [10] focused on tumor recurrence and
metastasis, support the very high detection rate for
distant metastasis for CCA (sensitivity 94%, specifi-
city 100%).
Conclusion
PET, and particularly the combination of PET and
CT, improves the results and impacts on the oncolo-
gical management in CCA. PET/PET-CT showed
higher sensitivity for intrahepatic CCA than for
extrahepatic CCA. PET/PET-CT is reliable for de-
tecting distant metastasis but unreliable for assessing
regional lymph node metastases.
Consensus statement
. PET-CT is recommended in the preoperative
staging of intrahepatic and extrahepatic CCA.
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Table I. Series of positron emission tomography (PET) and PET
associated with computed tomography (CT) reported in the
literature.
Author Patients Method
Fritcher (2001) [4] 15 PET
Kluge (2001) [5] 26 PET
Kato (2002) [6] 34 PET
Kim (2003) [7] 21 PET
Petrowsky (2006) [8] 41 PET-CT
Moon (2007) [9] 54 PET
Jadvar (2007) [10] 24 PET-CT
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